Posted by Michael Wonder on 16 Nov 2023
Ascendis Pharma resubmits NDA for TransCon PTH to the US FDA
15 November 2023 - Ascendis Pharma today announced that it has resubmitted its new drug application for TransCon PTH (palopegteriparatide) for the treatment of adults with hypoparathyroidism to the US FDA.
The resubmission follows the type A meeting held with the FDA in late August.
